Save 20% on Press Releases and More with NNW Prime! Click to View Details
MondayMar 13, 2017 7:30 pm

Charles & Colvard Ltd. (NASDAQ: CTHR) Starts Presentation at 29th Annual ROTH Conference

Charles & Colvard (NASDAQ: CTHR) is the original creator of Forever Classic™, Forever Brilliant® and Forever One™ moissanite gemstones for fine jewelry. Moissanite is unique, available in three color grades (colorless, near-colorless and faint color) and produced from silicon carbide (SiC) crystals. Charles & Colvard Created Moissanite® is sold with a Certificate of Authenticity and Limited Lifetime Warranty to wholesale distributors, manufacturers, retailers, TV shopping networks and designers as loose stones or set in a wide variety of quality metal setting options. Charles & Colvard, Ltd. also sells direct to consumers through its wholly owned operating subsidiary, charlesandcolvard.com, LLC, and…

Continue Reading

MondayMar 13, 2017 7:30 pm

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) Starts Presentation at 29th Annual Roth Conference

Syndax Pharmaceuticals (NASDAQ: SNDX) is a late-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics in oncology. The company’s lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. For more information, visit the company’s website at www.syndax.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a…

Continue Reading

MondayMar 13, 2017 7:30 pm

Inotek Pharmaceuticals Corp. (NASDAQ: ITEK) Starts Presentation at 29th Annual ROTH Conference

Inotek Pharmaceuticals (NASDAQ: ITEK) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The company’s lead product candidate, trabodenoson, is a selective adenosine mimetic currently in phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, visit the company’s website at www.inotekpharma.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social…

Continue Reading

MondayMar 13, 2017 7:00 pm

Revolution Lighting Technologies, Inc. (NASDAQ: RVLT) Starts Presentation at 29th Annual Roth Conference

Revolution Lighting Technologies (NASDAQ: RVLT) designs, manufactures, markets and sells light emitting diode (LED) lighting solutions focusing on the industrial, commercial and government markets in the United States, Canada and internationally. It markets a line of high-quality interior and exterior LED lamps and fixtures under the Seesmart brand. The company also supplies LED illumination for the signage industry, manufactures outdoor LED products, and offers a patented and licensed monitoring and smart grid control system for outdoor lighting applications. For more information, visit the company’s website at www. rvlti.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release…

Continue Reading

MondayMar 13, 2017 7:00 pm

The Joint Corp. (NASDAQ: JYNT) Starts Presentation at 29th Annual Roth Conference

The Joint (NASDAQ: JYNT) develops, owns, operates, franchises, supports and manages chiropractic clinics in the United States. The Joint is reinventing chiropractic care by making quality healthcare affordable for patients seeking pain relief and ongoing wellness. Its membership plans and packages eliminate the need for insurance, and our no-appointment policy, convenient hours and locations make care more accessible. As of July 20, 2016, it operated and franchised approximately 340 clinics. The company was founded in 2010 and is headquartered in Scottsdale, Arizona. For more information, visit the company’s website at www.thejoint.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication,…

Continue Reading

MondayMar 13, 2017 7:00 pm

Verastem, Inc. (NASDAQ: VSTM) Starts Presentation at 29th Annual Roth Conference

Verastem (NASDAQ: VSTM) is a biopharmaceutical company that focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company’s product candidate FAK inhibitor, VS-6063, is in phase I study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a phase II study in patients with non-small cell lung cancer; a phase II trial preceding surgery in mesothelioma; and a phase I/Ib clinical trial in combination with avelumab in patients…

Continue Reading

MondayMar 13, 2017 7:00 pm

Everspin Technologies, Inc. (NASDAQ: MRAM) Starts Presentation at 29th Annual ROTH Conference

Everspin Technologies (NASDAQ: MRAM) provides magnetoresistive random access memory (MRAM) solutions. The company’s MRAM solutions offer the persistence of non-volatile memory with the speed and endurance of random access memory (RAM), and enable the protection of mission critical data particularly in the event of power interruption or failure. The company’s MRAM solutions allow its customers in the industrial, automotive and transportation, and enterprise storage markets to design high performance, power efficient and reliable systems without the need for bulky batteries or capacitors. Everspin has shipped over 60 million MRAM units over the past eight years. For more information, visit the…

Continue Reading

MondayMar 13, 2017 7:00 pm

Profire Energy, Inc. (NASDAQ: PFIE) Starts Presentation at 29th Annual Roth Conference

Profire Energy (NASDAQ: PFIE) is an oilfield technology company that develops and sells combustion management technologies for the oil and gas. It also assists energy production companies in production and transportation of oil and natural gas. The company offers burner-management systems to ignite, monitor and manage the burner flames used in oilfield vessels as well as related products such as valves and fuel trains, air-plates, solar packages and flare stack igniter and nozzles. It also provides chemical-management systems to monitor and manage chemical-injection processes to ensure that optimal levels of chemicals are injected. For more information, visit the company’s website…

Continue Reading

MondayMar 13, 2017 7:00 pm

Inuvo, Inc. (NYSE: INUV) Starts Presentation at 29th Annual ROTH Conference

Inuvo (NYSE: INUV) is an internet advertising technology and digital publishing company that operates through two segments: Partner Network, and Owned and Operated Network. The Partner Network segment provides ValidClick, a service platform designed to help the owners of websites and mobile applications to monetize their properties, as well as offers a pay-per-click solution where advertisements are targeted to consumers based on content and behaviors. The Owned and Operated Network segment builds and operates websites under the ALOT brand. It operates local.alot.com, health.alot.com, finance.alot.com, careers.alot.com, travel.alot.com, living.alot.com, education.alot.com, and search.alot.com. For more information, visit the company’s website at www.inuvo.com. About NetworkNewsWire…

Continue Reading

MondayMar 13, 2017 7:00 pm

Adocia SA (ADOCF) Starts Presentation at 29th Annual ROTH Conference

Adocia SA (OTC: ADCOF) a clinical-stage biotechnology company, develops medicines using therapeutic molecules. Its product pipeline includes BioChaperone PDGF, which is in phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone Combo insulin that is in phase I/II clinical trials, as well as in pre-clinical stage for the treatment of diabetes; BioChaperone Lispro U100 that is in phase Ib clinical study for type 1 diabetes patients using an insulin pump; BioChaperone human insulin, which is in phase II clinical trials; and DriveIn, which is in preclinical stage for the treatment of oncology, as well as monoclonal antibodies…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000